ArticleArteriosclerosis, thrombosis, and vascular biology2019
Metabolomic Pattern Predicts Incident Coronary Heart Disease.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 99 citations in OpenAlex.
- Metabolic signature across Life's Essential 8 profiles is heterogenous and may predict cardiovascular disease and mortality.Metabolism open · 2026Article
- Longitudinal lipidomic markers of cardiac aging and risk of coronary heart disease in American Indians: the Strong Heart Family Study.GeroScience · 2026Article
- Metabolomics and Human Health: Progress, Insights, Challenges and the Concept of a Healthy Metabolome.Biomolecules · 2026Review
- Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study.PLoS medicine · 2026Article
- Metabolomic Markers of Left Ventricular Structure, Diastolic Function, and Risk of Coronary Heart Disease: A Longitudinal Study in American Indian Individuals.Journal of the American Heart Association · 2026Article
- MELODY: Mediation Analysis in Logistic Regression for High-Dimensional Mediators and a Binary Outcome.Genetic epidemiology · 2026Article
- MELODY: Mediation Analysis in Logistic Regression for High-Dimensional Mediators and a Binary Outcome.bioRxiv : the preprint server for biology · 2025Article
- Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.Journal of the American Heart Association · 2025Article
- Predictors of Fasting Endogenous Erythritol and Erythronate Concentrations in Humans: Cross-Sectional and Post-Bariatric Surgery Analyses.International journal of molecular sciences · 2025Article
- Early changes in urineMetabolomics : Official journal of the Metabolomic Society · 2025Article
- Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe?Cardiovascular research · 2025Review
- Plasma levels of polyols erythritol, mannitol, and sorbitol and incident coronary heart disease among women.European journal of preventive cardiology · 2025Article
- Identification of potential biomarkers for coronary slow flow using untargeted metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Machine Learning based Model Reveals the Metabolites Involved in Coronary Artery Disease.Biomedical engineering and computational biology · 2025Article
- Cord Blood Metabolite Profiles and Childhood Cardio-Metabolic Outcomes in a Population-Based Cohort.Annals of nutrition & metabolism · 2025Article
- Coronary heart disease and type 2 diabetes metabolomic signatures in the Middle East.Frontiers in endocrinology · 2025Article
- Metabolomics for the identification of biomarkers in endometriosis.Archives of gynecology and obstetrics · 2024Review
- Article
- Article
- Preliminary study of metabonomic changes during the progression of atherosclerosis in miniature pigs.Animal models and experimental medicine · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Objective- Alterations in the serum metabolome may be detectable in at-risk individuals before the onset of coronary heart disease (CHD). Identifying metabolomic signatures associated with CHD may provide insight into disease pathophysiology and prevention. Approach and Results- Metabolomic profiling (chromatography-mass spectrometry) was performed in 2232 African Americans and 1366 European Americans from the ARIC study (Atherosclerosis Risk in Communities). We applied Cox regression with least absolute shrinkage and selection operator to select metabolites associated with incident CHD. A metabolite risk score was constructed to evaluate whether the metabolite risk score predicted CHD risk beyond traditional risk factors. After 30 years of follow-up, we observed 633 incident CHD cases. Thirty-two metabolites were selected by least absolute shrinkage and selection operator to be associated with CHD, and 19 of the 32 showed significant individual associations with CHD, including a sugar substitute, erythritol. Theophylline (hazard ratio [95% CI] =1.16 [1.09-1.25]) and gamma-linolenic acid (hazard ratio [95% CI] =0.89 [0.81-0.97]) showed the greatest positive and negative associations with CHD, respectively. A 1 SD greater standardized metabolite risk score was associated with a 1.37-fold higher risk of CHD (hazard ratio [95% CI] =1.37 [1.27-1.47]). Adding the metabolite risk score to the traditional risk factors significantly improved model predictive performance (30-year risk prediction: Δ C statistics [95% CI] =0.016 [0.008-0.024], continuous net reclassification index [95% CI] =0.522 [0.480-0.556], integrated discrimination index [95% CI] =0.038 [0.019-0.065]). Conclusions- We identified 19 metabolites from known and novel metabolic pathways that collectively improved CHD risk prediction. Visual Overview- An online visual overview is available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.